We provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.

BMR has successfully developed a proprietary acid/brine leach process that enables it to achieve high metal recoveries from the different tailings deposits.

BMR Group PLC is listed on AIM under the ticker BMR.

The Company is focused on the recovery of lead and zinc from the tailings deposits of Zambia’s oldest mine at Kabwe.

Central Asia Metals plc (“CAML” or the “Company”) is an AIM-listed company incorporated in England & Wales, with operational headquarters in London. Its countries of operation are Kazakhstan, Chile and Mongolia. CAML produces copper in Kazakhstan and has a strategic interest in the Copper Bay project in Chile.

MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is focused in applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of chronic and acute diseases. MaxCyte's customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicine and active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs.

Palace Capital is a UK property investment company listed on the Alternative Investment Market (AIM) of The London Stock Exchange. The company is not sector specific and looks for opportunities where we can enhance the long-term income and capital value through asset management and strategic capital development.

RGF is a diversified food business and, following the sale of the Napier Brown sugar business, is focused on three pillar markets; cake decorating, food ingredients and premium bakery. All these markets have the benefit of being spread across a broad spectrum of trade channels: mainstream retail, specialist retail, manufacturing, wholesale, foodservice and export. All are also showing growth. It is proposed that all investment funds, either for capital projects or acquisition, will be focused on building RGF’s scale and presence and in these market sectors.